Every Form 4 that Biodesix, Inc. (BDSX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BDSX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDSX filings page.
Biodesix Inc. insider Jack W. Schuler, a ten percent owner and emeritus director, purchased 15,000 shares of common stock on August 12, 2026 at a weighted average price of $24.4661 per share, with trade prices ranging from $24.00 to $24.50. The shares were acquired indirectly through the Jack W. Schuler Living Trust, which now holds 555,810 shares. A separate indirect holding of 1,800,000 shares is reported for the Jack W. Schuler 2026 GRAT, for which Schuler is also sole trustee.
Biodesix Inc. insider Jack W. Schuler, a more-than-10% shareholder and emeritus director, reported two open-market purchases of common stock through the Jack W. Schuler Living Trust. On August 11, 2026, the trust purchased 13,700 shares at a weighted average price of $24.0081 per share, in multiple trades between $23.965 and $24.32. On August 10, 2026, it purchased 13,900 shares at a weighted average price of $24.2467 per share, in trades between $23.89 and $24.50. The filing also reports an indirect holding of 1,800,000 shares of common stock held by the Jack W. Schuler 2026 GRAT, for which Schuler is sole trustee. Reported amounts reflect exempt transfers between the Living Trust and related GRATs under Rule 16a-13, and the transactions were not executed under a Rule 10b5-1 trading plan.
Biodesix Inc. director and chairman John Patience reported a routine equity compensation transaction involving restricted stock units (RSUs) that converted into common shares. On June 30, 2026, he exercised 1,361 RSUs, receiving 1,361 shares of common stock, increasing his direct common stock holdings to 25,383 shares.
Following the transaction, he also directly holds 2,721 RSUs, each representing a contingent right to one share of common stock. These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to his continued service with Biodesix. The filing also lists indirect holdings of common stock held by his spouse, the John Patience Living Trust dated July 23, 1993, and Patience Enterprises LP.
Biodesix Inc. chairman John Patience exercised restricted stock units into common shares on March 31, 2026. He converted 1,361 RSUs into 1,361 shares of common stock at an exercise price of $0.00 per share. Following the transactions, he directly holds 24,022 common shares and 4,082 RSUs, with additional indirect holdings through Patience Enterprises LP, the John Patience Living Trust, and his spouse.
Biodesix Chief Development Officer Gary Anthony Pestano reported RSU vesting and a related tax sale. On February 20, 1,528 Restricted Stock Units were exercised into 1,528 shares of Biodesix common stock at $0.00 per share, as part of an annual vesting schedule starting February 20, 2025.
On February 23, 556 shares of common stock were sold at a weighted average price of $12.7756 per share by the issuer's broker to cover taxes due upon RSU vesting for certain employees, including Pestano. After these transactions, Pestano directly held 10,359 shares of common stock and 4,582 RSUs, which continue to vest in four equal annual installments.
Biodesix Inc.'s Chief Commercial Officer Kieran O'Kane reported insider transactions involving common stock and restricted stock units. On February 23, 2026, he sold 535 shares of common stock in an open-market transaction at a weighted average price of $12.7756 per share to cover taxes upon the vesting of restricted stock units. These shares were sold by the issuer's broker in multiple trades between $12.58 and $13.16 per share. On February 20, 2026, 1,469 restricted stock units were exercised and converted into 1,469 shares of common stock at $0.00 per share. Following these transactions, O'Kane held 9,819 shares of common stock and 4,406 restricted stock units, after adjustments for a one-for-twenty reverse stock split effective September 15, 2025. The RSUs vest in four equal annual installments starting February 20, 2025, generally conditioned on continued service.
Biodesix Inc (BDSX) CFO Robin Harper Cowie reported routine equity award activity and a small tax-related share sale. On February 20, 2026, 1,469 restricted stock units were exercised into 1,469 shares of common stock at a price of $0.00 per share, increasing directly held common stock to 16,766 shares.
On February 23, 2026, Cowie sold 535 shares of common stock in an open‑market transaction at a weighted average price of $12.7756 per share, leaving 16,231 common shares directly owned. Footnotes state these shares were sold automatically by the issuer’s broker to cover taxes upon RSU vesting, in multiple trades ranging from $12.58 to $13.16 per share.
Each RSU represents a right to receive one share of common stock, and the RSUs vest in four equal annual installments beginning February 20, 2025, generally subject to continued service. The holdings and award numbers reflect a one‑for‑twenty reverse stock split effective September 15, 2025.
Biodesix Inc Chief Accounting Officer Chris Vazquez reported equity transactions involving restricted stock units (RSUs) and common stock. On February 20, 2026, RSUs covering 563 shares were exercised for no cash cost, converting into the same number of common shares. Following this, on February 23, 2026, 211 common shares were sold in open-market transactions at a weighted average price of $12.7756 per share to cover taxes due upon RSU vesting, with individual sale prices ranging from $12.58 to $13.16. After these transactions, Vazquez directly held 1,586 common shares and 1,689 RSUs, with the RSUs scheduled to vest in four equal annual installments starting February 20, 2025.
Biodesix Inc. President & CEO Scott Hutton reported equity transactions involving company stock and restricted stock units. On February 20, 2026, 4,844 restricted stock units were exercised into 4,844 shares of common stock at $0.00 per share, increasing his direct common share holdings to 50,257 and leaving 14,531 RSUs outstanding. On February 23, 2026, 1,490 common shares were sold in open-market transactions at a weighted average price of $12.7756 per share, in a price range from $12.58 to $13.16, with the sale made automatically by the issuer’s broker to cover taxes upon RSU vesting. Following these transactions, he directly owned 48,767 shares of Biodesix common stock.
O'Kane Kieran reported multiple insider transaction types in a Form 4 filing for BDSX. The filing lists transactions totaling 3,784 shares at a weighted average price of $10.08 per share. Following the reported transactions, holdings were 9,469 shares.
Biodesix, Inc. Chief Accounting Officer Chris Vazquez reported equity award activity and a small share sale. On February 9, 2026, RSUs were converted into 263 shares of Common Stock, increasing direct holdings to 1,335 shares, and RSU positions were adjusted following a one-for-twenty reverse split.
On February 10, 2026, Vazquez executed an open‑market sale of 101 Common shares at a weighted average price of $10.0841, conducted automatically to cover taxes upon RSU vesting, leaving 1,234 Common shares held directly and 234 RSUs outstanding, which vest over time subject to continued service.
Biodesix, Inc. President & CEO Scott Hutton reported equity award activity and a related share sale. On February 9, 2026, he acquired 9,998 shares of Common Stock through the exercise of restricted stock units (RSUs), bringing his direct Common Stock holdings to 48,972 shares.
On February 10, 2026, 3,559 Common Shares were sold in an open-market transaction at a weighted average price of $10.0841 to cover taxes due upon RSU vesting, leaving him with 45,413 Common Shares held directly. RSU activity included the conversion of 610 RSUs that fully vested and 9,388 RSUs that remain outstanding, with vesting schedules tied to continued service and figures adjusted for a one-for-twenty reverse stock split effective September 15, 2025.
Biodesix Inc. CFO Robin Harper Cowie reported equity compensation activity tied to restricted stock units (RSUs). On February 9, 2026, RSUs were converted into 2,584 shares of Common Stock, and RSU balances were updated, including 2,426 unvested RSUs after adjustment for a prior reverse split.
On February 10, 2026, Cowie executed an automatic open-market sale of 941 Common shares at a weighted average price of $10.0841 to cover taxes upon RSU vesting, leaving 15,297 Common shares held directly.
Biodesix Inc. Chief Development Officer Gary Anthony Pestano reported equity transactions involving company stock. On February 9, 2026, he acquired 1,481 shares of Common Stock through the exercise/conversion of restricted stock units (RSUs), bringing his direct holdings to 9,927 shares.
On February 10, 2026, 540 shares of Common Stock were sold at a weighted average price of $10.0841 per share, automatically to cover taxes upon RSU vesting. After this tax-related sale, Pestano directly owned 9,387 shares of Biodesix Common Stock. The filing also notes RSU grants that vest over time and that the reported RSU numbers reflect a one-for-twenty reverse stock split effective September 15, 2025.
Biodesix Inc. reported insider share purchases by entities associated with major shareholder Jack W. Schuler. On January 23, 2026, the Jack W. Schuler Living Trust bought 80,000 shares of Biodesix common stock at a weighted average price of $11.8084, and on January 26, 2026 it bought an additional 20,000 shares at a weighted average price of $11.8032. After these transactions, the Living Trust held 1,563,210 shares of common stock, and the Jack W. Schuler 2025 GRAT held 750,000 shares, both reported as indirectly owned. The prices reflect multiple individual trades within stated ranges, and Schuler is disclosed as the sole trustee of both trusts.
Biodesix Inc. 10% owner Jack W. Schuler, through his living trust, increased his indirect stake in the company. On January 22, 2026, the Jack W. Schuler Living Trust purchased 82,465 shares of Biodesix common stock in open-market transactions at a weighted average price of $10.9569 per share, with individual trades ranging from $10.675 to $11.10. Following this purchase, the living trust held 1,463,210 shares of Biodesix common stock indirectly for Schuler as sole trustee. A separate vehicle, the Jack W. Schuler 2025 GRAT, is shown as indirectly holding an additional 750,000 shares of Biodesix common stock, also with Schuler as sole trustee.
Biodesix, Inc. insider Chris Vazquez, the Chief Accounting Officer, reported routine equity transactions involving restricted stock units (RSUs) and related tax sales. On January 15, 2026, 219 RSUs vested and were converted into an equal number of shares of Biodesix common stock at an exercise price of $0, consistent with each RSU representing one share. On January 16, 2026, 83 of these common shares were automatically sold at a weighted average price of $8.1493 per share to cover taxes due upon vesting, with prices ranging from $8.10 to $8.28. Following these transactions, Vazquez directly held 1,072 shares of common stock and 436 RSUs, which vest in four equal annual installments from January 15, 2024. The reported share counts have been adjusted for a one-for-twenty reverse stock split effective September 15, 2025.
Biodesix Inc's Chief Development Officer, Gary Pestano, reported routine equity compensation activity. On January 15, 2026, 805 restricted stock units converted into 805 shares of Biodesix common stock at an exercise price of $0 per share, reflecting previously granted RSUs that each represent one share. The RSU figures and related share amounts have been adjusted for a one-for-twenty reverse stock split effective September 15, 2025.
On January 16, 2026, 298 shares of common stock were sold at a weighted average price of $8.1493 per share, with the shares automatically sold to cover taxes due upon RSU vesting. After these transactions, Pestano beneficially owned 8,446 shares of common stock and 1,609 RSUs, which vest in four equal annual installments starting January 15, 2024, generally contingent on continued service.
Biodesix Inc. Chief Commercial Officer Kieran O'Kane reported routine equity compensation activity. On January 15, 2026, 805 restricted stock units (RSUs) were converted into 805 shares of Common Stock at an exercise price of $0, reflecting prior awards adjusted for a one-for-twenty reverse stock split effective September 15, 2025. These RSUs are part of a grant that vests in four equal annual installments starting January 15, 2024, generally conditioned on continued service.
On January 16, 2026, 298 shares of Common Stock were sold at a weighted average price of $8.1493 per share, with prices ranging from $8.10 to $8.28, to cover taxes due upon RSU vesting. After these transactions, O'Kane directly held 7,869 shares of Common Stock and 1,609 RSUs.
Biodesix Inc. President & CEO Scott Hutton reported routine equity award activity and a small share sale. On January 15, 2026, 2,633 restricted stock units (RSUs) vested and were converted into 2,633 shares of Biodesix common stock at an exercise price of $0, reflecting a stock-based compensation award. The RSU and share counts have been adjusted for a one-for-twenty reverse stock split effective September 15, 2025.
On January 16, 2026, 970 shares of common stock were sold at a weighted-average price of $8.1493 per share to automatically cover taxes due upon the RSU vesting. After these transactions, Hutton directly held 38,974 shares of common stock and 5,265 RSUs, which continue to vest in four equal annual installments starting January 15, 2024.
Biodesix, Inc. (BDSX) CFO, Secretary & Treasurer Robin Harper Cowie reported RSU vesting and related tax-share sales. On January 15, 2026, 805 restricted stock units were converted into the same number of Biodesix common shares at an exercise price of $0, increasing her direct common stock holdings to 13,952 shares and RSU holdings to 1,609 units after the transaction.
On January 16, 2026, she sold 298 shares of common stock at a weighted average price of $8.1493 per share. According to the disclosure, these shares were sold automatically by the issuer's broker to cover taxes due upon RSU vesting. Following the sale, she directly owned 13,654 shares of common stock. The filing notes that all share and unit numbers reflect a one-for-twenty reverse stock split effective September 15, 2025, and that the RSUs vest in four equal annual installments starting January 15, 2024.
Biodesix director Jean M. Franchi reported new equity awards dated January 2, 2026. She received 8,164 restricted stock units (RSUs), each representing one share of Biodesix common stock. These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally conditioned on her continued service, and a portion is structured as deferred RSUs that will be settled in shares after her separation from the company. She was also granted 6,354 stock options with an exercise price of $6.46 per share, vesting in four substantially equal installments on the same 2026 dates, also tied to continued service.
Biodesix director Matthew Strobeck reported new equity awards. On January 2, 2026, he received 6,804 restricted stock units (RSUs), each representing one share of Biodesix common stock. These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026 and some are deferred so the underlying shares will be delivered after his separation from service.
On the same date, he was also granted 6,354 stock options with an exercise price of $6.46 per share, vesting in four substantially equal installments on the same 2026 dates and expiring on January 1, 2036. All awards are generally subject to his continued service as a director.
Biodesix Inc. director Hany Massarany reported new equity awards. On January 2, 2026, he received 7,484 restricted stock units (RSUs), each representing one share of Biodesix common stock. These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally conditioned on continued service.
Some of the RSUs are deferred, with the underlying shares to be issued after his separation from service. Massarany was also granted stock options for 6,354 shares at an exercise price of $6.46 per share, vesting in four substantially equal installments on the same 2026 dates, also generally subject to continued service.
Biodesix Inc. director and 10% owner Lawrence T. Kennedy Jr. reported awards of restricted stock units (RSUs) and stock options dated January 2, 2026. He received 5,443 RSUs, each representing a right to one share of common stock, which vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally contingent on continued service and with no expiration date. These include deferred RSUs that will be settled in shares after his separation from service. He also received stock options for 6,354 shares at an exercise price of $6.46 per share, vesting on the same quarterly 2026 schedule and expiring on January 1, 2036.
Biodesix Inc. reported an insider stock option grant to its Chief Commercial Officer, Kieran O'Kane. On January 2, 2026, O'Kane was awarded stock options representing the right to buy 27,000 shares of Biodesix common stock at an exercise price of $6.46 per share. These options were granted at no cost to him and are held directly.
The option grant has a long-term structure. It vests in forty-eight substantially equal monthly installments starting January 2, 2026, generally requiring O'Kane to continue serving at the company through each vesting date. The options are scheduled to expire on January 1, 2036 if not exercised.
Biodesix, Inc. reported an insider equity award to a senior executive. Chief Accounting Officer Chris Vazquez was granted stock options covering 12,000 shares of Biodesix common stock on January 2, 2026.
The options have an exercise price of $6.46 per share and expire on January 1, 2036. They vest in forty-eight equal monthly installments starting January 2, 2026, generally requiring Vazquez to remain in service through each vesting date. Following this grant, Vazquez beneficially owns 12,000 stock options directly.
Biodesix (BDSX) reported a routine insider transaction for Chief Accounting Officer Chris Vazquez. On 11/10/2025, 31 shares of common stock were acquired upon the vesting of restricted stock units, adjusted for the one-for-twenty reverse stock split effective September 15, 2025. To cover taxes upon vesting, 13 shares were automatically sold at $7.62. Following these transactions, Vazquez directly owned 936 shares. Each RSU represents one share of common stock, and the RSUs vest in sixteen successive quarterly installments measured from February 8, 2022 and have no expiration date.
Biodesix (BDSX) insider transaction: Chief Development Officer Gary Pestano reported RSU vesting and a small tax sale on 11/10/2025. A total of 69 shares were issued upon RSU settlement (code M), and 23 shares of common stock were sold at $7.62 to cover taxes tied to the vesting.
Following these transactions, Pestano beneficially owned 7,939 shares directly. The filing notes all share figures reflect the one‑for‑twenty reverse stock split effective September 15, 2025, and that each RSU represents one share of common stock.
Biodesix (BDSX) Chief Commercial Officer Kieran O’Kane reported RSU vesting and a related sale on 11/10/2025. He acquired 75 shares of common stock upon RSU vesting (code M) and sold 25 shares at $7.62 to cover taxes upon vesting. Following these transactions, he directly owned 7,362 shares of common stock and held 73 RSUs.
The filing notes all figures reflect the 1-for-20 reverse stock split effective September 15, 2025. The RSUs vest in sixteen successive quarterly installments measured from February 8, 2022, subject to continued service. Prior ownership includes 309 shares purchased under the Employee Stock Purchase Plan on September 2, 2025.
Biodesix (BDSX) disclosed insider activity by its President & CEO and Director, Scott Hutton. On 11/10/2025, 611 shares of Common Stock were acquired upon RSU vesting, followed by an automatic sale of 189 shares at $7.62 to cover taxes. Following these transactions, the reporting person directly beneficially owned 37,311 shares.
The amounts reflect the one-for-twenty reverse stock split effective September 15, 2025. After the vesting event, 610 RSUs remained outstanding, with RSUs vesting in successive quarterly installments measured from February 8, 2022.
Biodesix (BDSX) reported an insider transaction by its CFO, Secretary & Treasurer, Robin Harper Cowie. On 11/10/2025, 158 shares of Common Stock were acquired upon the vesting of restricted stock units, adjusted for the one-for-twenty reverse stock split effective September 15, 2025. To cover taxes from the vesting, 50 shares were sold at $7.62. Following these transactions, the reporting person beneficially owned 13,147 shares directly.
John Patience, a director of Biodesix, Inc. (BDSX), reported receipt of 1,144 restricted stock units (RSUs) effective 09/30/2025. The filing notes a one-for-twenty reverse stock split effective 09/15/2025 and states the reported share figures have been adjusted for that split. The RSUs represent contingent rights to receive one share each and vest in three substantially equal installments on 06/30/2025, 09/30/2025, and 12/31/2025, generally subject to continued service, and have no expiration date. The report discloses indirect holdings through Patience Enterprises LP (107,664 shares), the John Patience Living Trust dated 7/23/1993 (241,480 shares), and holdings attributed to a spouse (2,649 shares). The Form is signed by Robin H. Cowie as attorney-in-fact for John Patience on 10/02/2025.